A peer-reviewed article in the Journal of Cancer Therapy titled, "VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan," supports the use of IceCure Medical's cryoablation technology for certain breast cancer tumors.
Follow Israel Hayom on Facebook and Twitter
The lead author of the article was Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.
The independent study, conducted at the St. Marianna University Breast & Imaging Center in Kawasaki City, Japan enrolled eight female patients ages 53 to 72 with a mean age 62 years who were diagnosed with invasive ductal carcinoma (IDC) tumors. Percutaneous ultrasound-guided cryoablation of the breast tumor was performed using IceCure's ProSense, under local anesthesia, without the need of subsequent resection. The procedure took an average of 40 minutes on average. All patients received radiation and endocrine therapies (RT, ET). The patients were followed using vacuum-assisted biopsy (VAB), mammography (MG), magnetic resonance imaging (MRI), and Moiré Topography for cosmetic outcomes.
The article concludes that although conducted on a limited number of patients, the data shows feasibility of cryoablation for the elimination of small malignant lesions in the breast, along with promising safety prospects.
In addition, the article said, percutaneous cryoablation of early-stage low-risk breast cancer tumors smaller than 15 mm presents a potential substitute for lumpectomy, offering encouraging short- to mid-term oncology results with good cosmesis outcomes. Patients would be able to benefit from local anesthesia in an outpatient setting and shorter recovery period.
"We are excited to see the publication of this data from an independent study which further supports the use of our ProSense Cryoablation System to eliminate small malignant lesions in the breast instead of performing breast surgery under general anesthesia (i.e lumpectomy)," commented IceCure CEO Eyal Shamir.
